Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17766972 | 1.00 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17766918 | 1.00 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17766949 | 0.92 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17766952 | 0.92 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17766967 | 0.90 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17767189 | 0.90 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17767216 | 0.90 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17766973 | 0.90 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17767143 | 0.90 | GPR139 (1.00) | GPR139 | |
| SCHEMBL17766974 | 0.90 | GPR139 (1.00) | GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173161-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | claimed |
| EP-3536324-B1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-10-06 | — | — | EP | claimed |
| CN-107108531-B | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2020-10-20 | — | — | CN | claimed |
| US-20200129518-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2020-04-30 | — | — | US | claimed |
| US-10561662-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | claimed |
| EP-3221298-B1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE DERIVATIVES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICALS CO (JP) | 2019-04-03 | — | — | EP | claimed |
| US-20190070187-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2019-03-07 | — | — | US | claimed |
| US-10159677-B2 | 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-25 | — | — | US | claimed |
| US-20170348319-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2017-12-07 | — | — | US | claimed |
| EP-3221298-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | Takeda Pharmaceutical Company Limited (JP) | 2017-09-27 | — | — | EP | claimed |
| US-9770450-B2 | 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | claimed |
| US-20170095480-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2017-04-06 | — | — | US | claimed |
| US-9556130-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-31 | — | — | US | claimed |
| WO-2016081736-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-26 | — | — | WO | claimed |
| US-20160145218-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2016-05-26 | — | — | US | claimed |
| CN-112062730-B | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2023-09-29 | — | — | CN | disclosed |
| US-11173161-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| WO-2016081736-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-26 | — | — | WO | disclosed |
| US-20160145218-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145218-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070187-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
| US-20200129518-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
| US-20170095480-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
| US-20160145218-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
| US-10561662-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
| US-10159677-B2 | 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
| US-20170348319-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
| US-11173161-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.